Literature DB >> 27864520

Ibrutinib monotherapy in relapsed/refractory CNS lymphoma: A retrospective case series.

Kamal Chamoun1, Sylvain Choquet1, Eileen Boyle1, Caroline Houillier1, Delphine Larrieu-Ciron1, Ahmad Al Jijakli1, Vanessa Delrieu1, Vincent Delwail1, Franck Morschhauser1, Khê Hoang-Xuan1, Carole Soussain2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27864520     DOI： 10.1212/WNL.0000000000003420

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  21 in total

1.  Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant MYD88 and wildtype CD79.

Authors:  Andrew L Deng; Yu Ri Kim; Emily A Lichtenstein; Owen A O'Connor; Changchun Deng
Journal:  Haematologica       Date:  2017-03-24       Impact factor: 9.941

Review 2.  Introduction of novel agents in the treatment of primary CNS lymphoma.

Authors:  Christian Grommes; Lakshmi Nayak; Han W Tun; Tracy T Batchelor
Journal:  Neuro Oncol       Date:  2019-02-19       Impact factor: 12.300

Review 3.  Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents.

Authors:  Andrés José María Ferreri
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

4.  Primary Central Nervous System Lymphoma: Long-Term Treatment Outcomes and Cost-Analysis from a Retrospective Study of High-Dose Methotrexate Based Chemoimmunotherapy and Reduced Dose Radiation Therapy Approach.

Authors:  Radhakrishnan Vs; Podder D; Mukherjee H; Mandal P; Achari R; Sen S; Dey D; Arun I; Latif Z; Arora N; Nag A; Kumar J; Javed R; Bhave Sj; Parihar M; Mishra Dk; Chandy M; Nair R
Journal:  Indian J Hematol Blood Transfus       Date:  2021-05-18       Impact factor: 0.900

5.  Experience with nasogastric tube administration of tirabrutinib in the treatment of an elderly patient with primary central nervous system lymphoma.

Authors:  Hiromasa Yoshioka; Takeshi Okuda; Takayuki Nakao; Mitsugu Fujita; Jun C Takahashi
Journal:  Int Cancer Conf J       Date:  2021-06-05

Review 6.  Treatment Options for Recurrent Primary CNS Lymphoma.

Authors:  Leon D Kaulen; Joachim M Baehring
Journal:  Curr Treat Options Oncol       Date:  2022-10-07

7.  Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study.

Authors:  Caroline Houillier; Hervé Ghesquières; Cécile Chabrot; Carole Soussain; Guido Ahle; Sylvain Choquet; Emmanuelle Nicolas-Virelizier; Jacques-Olivier Bay; Jacques Vargaftig; Claude Gaultier; Valérie Touitou; Nadine Martin-Duverneuil; Nathalie Cassoux; Magali Le Garff-Tavernier; Myrto Costopoulos; Pierre Faurie; Khê Hoang-Xuan
Journal:  J Neurooncol       Date:  2017-04-21       Impact factor: 4.130

8.  Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma.

Authors:  Tarec Christoffer El-Galaly; Chan Yoon Cheah; Mette Dahl Bendtsen; Grzegorz S Nowakowski; Roopesh Kansara; Kerry J Savage; Joseph M Connors; Laurie H Sehn; Neta Goldschmidt; Adir Shaulov; Umar Farooq; Brian K Link; Andrés J M Ferreri; Teresa Calimeri; Caterina Cecchetti; Eldad J Dann; Carrie A Thompson; Tsofia Inbar; Matthew J Maurer; Inger Lise Gade; Maja Bech Juul; Jakob W Hansen; Staffan Holmberg; Thomas S Larsen; Sabrina Cordua; N George Mikhaeel; Martin Hutchings; John F Seymour; Michael Roost Clausen; Daniel Smith; Stephen Opat; Michael Gilbertson; Gita Thanarajasingam; Diego Villa
Journal:  Eur J Cancer       Date:  2018-02-21       Impact factor: 9.162

Review 9.  New roles for B cell receptor associated kinases: when the B cell is not the target.

Authors:  Phuong-Hien Nguyen; Emanuel Niesen; Michael Hallek
Journal:  Leukemia       Date:  2019-01-30       Impact factor: 11.528

10.  Efficacy and Safety of Ibrutinib in Central Nervous System Lymphoma: A PRISMA-Compliant Single-Arm Meta-Analysis.

Authors:  Liwei Lv; Xuefei Sun; Yuchen Wu; Qu Cui; Yuedan Chen; Yuanbo Liu
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.